[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342381-105":59,"doc-detail-342381-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","n-glycan-profiling-of-tissue-samples-to-aid-breast-cancer-subtyping","N-glycan profiling of tissue samples to aid breast cancer subtyping","","N-glycan profiling is used to support breast cancer subtyping beyond receptor-based intrinsic classification. N-glycan profiles from 145 tumor samples and 10 clinically normal breast tissues are measured by MALDI-TOF mass spectrometry, then quantified and analyzed with reproducibility-optimized statistics in R using the Wilcoxon rank sum test. Ninety-two N-glycans are detected, with subtype-specific variations. Distinct alterations are observed in mucinous and triple-negative cancers, while normal tissues show higher bisecting-motif abundance linked to clinical parameters such as tumor size, proliferation rate, lymphovascular invasion, and lymph-node metastases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/n-glycan-profiling-of-tissue-samples-to-aid-breast-cancer-subtyping/342381/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/n-glycan-profiling-of-tissue-samples-to-aid-breast-cancer-subtyping/342381.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were N-glycan profiles generated for tumor and healthy breast tissues?","Question",{"text":112,"@type":113},"N-glycan profiles for 145 tumors and 10 healthy tissues were determined using MALDI-TOF mass spectrometry, followed by quantification and statistical analysis in R.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which breast cancer subtypes were distinguished in the study?",{"text":117,"@type":113},"Tumor samples were classified into Mucinous, Lobular, No-Special-Type, HER2-positive, and Triple-Negative Breast Cancer subtypes.",{"name":119,"@type":110,"acceptedAnswer":120},"What N-glycan features differed most between subtypes?",{"text":121,"@type":113},"Mucinous tumors showed the most distinct changes with many significantly altered N-glycans, while triple-negative cancers exhibited additional mannose-associated N-glycans; branching and fucosylation differences were linked to Luminal subtypes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342381,1790614234,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nN‑glycan profiling of tissue samples to aid breast cancer subtyping  \nIva Benesova1, Rudolf Nenutil2, Adam Urminsky1,3, Erika Lattova 3,4, Lukas Uhrik1, Peter Grell5, Filip Zavadil Kokas1, Jana Halamkova5, Zbynek Zdrahal3,4, Borivoj Vojtesek1, MilosV. Novotny 1,6* & Lenka Hernychova1*  \nBreast cancer is a highly heterogeneous disease. Its intrinsic subtype classification for diagnosis and choice of therapy traditionally relies on the presence of characteristic receptors. Unfortunately, this classification is often not sufficient for precise prediction of disease prognosis and treatment efficacy. The N‑glycan profiles of 145 tumors and 10 healthy breast tissues were determined using Matrix‑Assisted Laser Desorption‑Ionization Time‑of‑Flight Mass Spectrometry. The tumor samples were classified into Mucinous, Lobular, No‑Special‑Type, Human Epidermal Growth Factor 2 + , and Triple‑Negative Breast Cancer subtypes. Statistical analysis was conducted using the reproducibility‑ optimized test statistic software package in R, and the Wilcoxon rank sum test with continuity correction. In total, 92 N‑glycans were detected and quantified, with 59 consistently observed in over half of the samples. Significant variations in N‑glycan signals were found among subtypes. Mucinous tumor samples exhibited the most distinct changes, with 28 significantly altered N‑glycan signals. Increased levels oftri‑ and tetra‑antennary N‑glycans were notably present in this subtype. Triple‑ Negative Breast Cancer showed more N‑glycans with additional mannose units, a factor associated with cancer progression. Individual N‑glycans differentiated Human Epidermal Growth Factor 2 + , No‑Special‑Type, and Lobular cancers, whereas lower fucosylation and branching levels were found in N‑glycans significantly increased in Luminal subtypes (Lobular and No‑Special‑Type tumors) . Clinically normal breast tissues featured a higher abundance of signals corresponding to N‑glycans with bisecting moiety. This research confirms that histologically distinct breast cancer subtypes have a quantitatively unique set of N‑glycans linked to clinical parameters like tumor size, proliferativerate, lymphovascular invasion, and metastases to lymph nodes. The presented results provide novel information that N‑glycan profiling could accurately classify human breast cancer samples, offer stratification of patients, and ongoing disease monitoring.  \nAbbreviations  \nMALDI-TOF  \nMS ROTS CA 15-3  \nCEAIHCER PR HER2  \nKi67 LLALB LX  \nMatrix-assisted laser desorption-ionization time-of-flight Mass spectrometry  \nReproducibility-optimized test statistic Cancer antigen 15-3  \nCarcinoembryonic antigen Immunohistochemical Estrogen receptor Progesterone receptor  \nHuman epidermal growth factor 2  \nMarker of proliferation Ki-67  \nLuminal  \nLuminal A  \nLuminal B  \nLuminal X  \n1Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. 2Department of Pathology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. 3National Center for Biomolecular Research, Faculty of Science, Masaryk University, Kotlarska 2, Brno, Czech Republic. 4Central European Institute of Technology, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. 5Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic. 6Department of Chemistry, Indiana University, 800 E. Kirkwood Avenue, Bloomington, IN 47405, USA.* email: [novotny@indiana.edu](novotny@indiana.edu); [lenka.hernychova@mou.cz](lenka.hernychova@mou.cz)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nTNBC Triple-negative breast cancer  \nEGFR Epidermal growth factor receptor  \nAR Androgen receptor  \nNST No-specified-type  \nMUC Mucinous carcinomas  \nACN Acetonitrile  \nTFA Trifluoroacetic acid  \nDMF N, N-dimet","cbCaiq5a4G5E2spv","https://ap.wps.com/l/cbCaiq5a4G5E2spv","pdf",4082169,16,"English","# Overview\n## Study design and sample cohort\n## N-glycan detection and quantification\n## Subtype classification and statistical analysis\n## Key findings across breast cancer subtypes\n## Clinical relevance and potential monitoring","[{\"question\":\"How were N-glycan profiles generated for tumor and healthy breast tissues?\",\"answer\":\"N-glycan profiles for 145 tumors and 10 healthy tissues were determined using MALDI-TOF mass spectrometry, followed by quantification and statistical analysis in R.\"},{\"question\":\"Which breast cancer subtypes were distinguished in the study?\",\"answer\":\"Tumor samples were classified into Mucinous, Lobular, No-Special-Type, HER2-positive, and Triple-Negative Breast Cancer subtypes.\"},{\"question\":\"What N-glycan features differed most between subtypes?\",\"answer\":\"Mucinous tumors showed the most distinct changes with many significantly altered N-glycans, while triple-negative cancers exhibited additional mannose-associated N-glycans; branching and fucosylation differences were linked to Luminal subtypes.\"}]","N-glycan profiling of tissue samples to aid breast cancer subtyping | PDF",1790046367,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/178852d946db123f31c05892292cbf35.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbc24197f492062d68f2e0d121a8be10.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/921c650259ce4ccb2b0d23bc2c3955c3.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa18db5594ad034312081f452d76ca9d.webp",980,1287]